UT MD Anderson Presentations at ASTRO

ARRO 01 — ARRO Brachytherapy — Didactic session (Part I)

8–9:30 a.m. | Room 160

Optimizing precision with MARS LDR brachytherapy for prostate cancer treatment in the monotherapy, combined and salvage settings
8:24–8:36 a.m.
Presenter: Steven Frank, M.D.

Workshop 01 — Physics insights for advanced clinical practice: Adaptive, re-irradiation, AI and trials

8 a.m.–5:30 p.m. | Room 204

Opening keynote: The physics advances in modern radiotherapy
8:05–9:05 a.m.
Presenter: David Jaffray, Ph.D.

Session 1 — Re-irradiation: Data driven decision-making: Imaging/dose escalation in trials
10:35–11:05 a.m.
Presenter: Kristy Brock, Ph.D.

Workshop 03 — Brachytherapy didactic session — General attendees (Part I)

10–11 a.m. | Room 160

Optimizing precision with MARS LDR brachytherapy for prostate cancer treatment in the monotherapy, combined, and salvage settings
10–10:12 a.m.
Presenter: Steven Frank, M.D.

ARRO 03 —  ARRO Day

11 a.m.–5:15 p.m. | Room 156

Keynote: Financial toxicity
4:05–4:30 p.m.
Presenter: Fumiko Chino, M.D.

ARRO 04 — ASTRO-ARRO Medical student workshop

12–4 p.m. | Room 153

Shaping your path: Academic and extracurricular excellence in RadOnc panel
12:10–12:20 p.m.
Presenter: Rehema Thomas, M.D.

Intern Year and Transitioning to RadOnc Residency w/ Q&A
3:23–3:34 p.m.
Presenter: Cira Mollings Puentes, M.D.

Workshop 05 — ACGME workshop: Review committee update and accreditation info you need for your program

1–2:30 p.m. | Room 254

RO review committee information and RC program requirement changes and initiatives
1–1:45 p.m.
Presenter: Prajnan Das, M.D.

PS 01 — Presidential Symposium — Data to dialogue: Communicating radiotherapy's value to advance care — Session I: Organ-preservation: The undersung value of RT

8:20–9:40 a.m. | Grand Ballroom

Head & neck/ GU treatment
8:51–9:06 a.m.
Presenter: Steven Frank, M.D.

ASPP 01 — 2026 aspiring scientists and physicians program

11 a.m.–3:30 p.m. | Room 153

Mentoring lighting rounds
1:45–2:15 p.m.
Presenter: Rehema Thomas, M.D.

CT 01 — Clinical trials session

1:30–3 p.m. | Grand Ballroom

Abstract 6 — Evaluation of PAM50 molecular subtypes in post-prostatectomy salvage radiotherapy: An NRG oncology-RTOG 0534 analysis
1:30–1:40 p.m.
Presenter: Shuang Zhao, M.D.

Abstract 9 — Six-year overall survival of nivolumab following stereotactic ablative radiotherapy in early-stage non-small cell lung cancer: Randomized I-SABR trial
2–2:10 p.m.
Presenter: Joe Chang, M.D., Ph.D.

Workshop 07 — When disaster strikes: Safeguarding radiotherapy's value and continuity across catastrophic events

2:30–4 p.m. | Room 257
Moderator: Fumiko Chino, M.D.

QP 02 — Advances in pediatric radiotherapy and side effect mitigation

3–4 p.m. | Room 256

Abstract 1007 — Radiation oncology workflow-integrated coronary artery disease risk calculator for pediatric and adolescent cancer patients
3:10–3:15 p.m.
Presenter: Rebecca Howell, Ph.D.

Abstract 1008 — Delays in adjuvant therapy initiation for Wilms tumor: Institutional patterns and clinical impact on disease control
3:15–3:20 p.m.
Presenter: Troy Kleber, M.D.

SS 02 — Escalate, de-escalate or substitute? Trials shaping prostate cancer care

3–4 p.m. | Room 205
Moderator: Seungtaek Choi, M.D.

SS 03 — Technologically driven strategies in HPV related OPSCC

3–4 p.m. | Room 162

Abstract 113 — MR-ADAPTOR: Randomized Phase 2 trial of weekly MRI-guided volumetric adaptation and elective neck deintensification for low-risk HPV-associated OPSCC
3:30–3:40 p.m.
Presenter: Warren Floyd, M.D., Ph.D.

SS 05 — Advances in radiation response and microenvironment

3–4 p.m. | Room 204

Abstract 123 — Clonal hematopoiesis following radiation therapy as a novel predictor of cancer control and survival: Analyses from prospective trials
3:20–3:30 p.m.
Presenter: Kevin Nead, M.D.

EDU 03 — Nonoperative and preoperative local management of breast cancer: From data to shared decisions

3–4 p.m. | Room 258

Nonoperative management after neoadjuvant systemic therapy: Image guided biopsy strategies, omission of surgery, and patient reported outcomes
3:02–3:17 p.m. 
Presenter: Henry Mark Kuerer, M.D., Ph.D.

International 01 — Radiotherapy under debate: Defending the indication in Latin America through evidence, value, and access (session in Spanish)

3–4 p.m. | Room 156

CASE 2 — Laryngeal cancer (T2-T3 N0) function vs removal: The organ preservation debate
3–3:10 p.m.
Presenter: Amy Moreno, M.D.

EDU 06 — Diagnosis to decision: Distinguishing and managing radiation necrosis vs. recurrent brain metastases

5–6 p.m. | Room 157
Moderator: Martin Tom, M.D.

Question and answers
5:47–6 p.m. 
Presenter: Martin Tom, M.D.

EDU 07 — Beyond the bone: Difficult cases that stretch the definitions of palliative radiotherapy

5–6 p.m. | Room 259    

Breast cancer with fungating breast mass
Presenter: Chelain Goodman, M.D., Ph.D.

SS 09 — From trials to real-world impact

5–6 p.m. | Room 109
Moderator: Kevin Nead, M.D.

SS 11 — Interventions to advance healthcare access in radiation oncology

8–9 a.m. | Room 107

Abstract 153 — Alternative cancer treatment clinics in North America: Evidence gaps, regulatory concerns and financial burden
8:40–8:50 a.m.
Presenter: Zakaria El Kouzi, M.D.

EDU 17 — Spatially fractionated radiation therapy (SFRT): Biological mechanisms and clinical translation

8–9 a.m. | Room 204   

Tumor-immune dynamics in SFRT: Modeling response, competition and treatment optimization
8:17–8:32 a.m.
Presenter: Heiko Enderling, Ph.D.

EDU 19 — ASTRO GU guideline session: Radiation therapy for bladder cancer and localized prostate cancer: A case-based interactive discussion

10:45 a.m.–12 p.m. | Room 253

Hypofractionated RT for localized prostate cancer
11:17–11:45 a.m.
Presenter: Karen Hoffman, M.D.

SS 22 — Some crHEME with your coffee? A winning blend of radiation and systemic therapy in hematologic malignancies

10:45 a.m.–12 p.m. | Room 259
Moderator: Susan Wu, M.D.

SS 23 — Emerging pathways and targeted therapies

3–4 p.m. | Room 153
Moderator: Ann Klopp, M.D., Ph.D.

QP 08 — CNS metastases and LMD: Patient selection, treatment strategy and outcomes

3–4 p.m. | Room 254

Abstract 1047 — Predicting survival and treatment completion of proton craniospinal irradiation in leptomeningeal disease: A prognostic nomogram
3:30–3:35 p.m.
Presenter: Tejaswi Kanala, M.D., M.B.B.S.

SS 24 — Innovations in rare cutaneous and soft tissue malignancies

3–4 p.m. | Room 205

Discussion 
3:50–4 p.m. 
Presenter: Devarati Mitra, M.D., Ph.D.

SS 31 — Mechanisms of resistance and normal tissue toxicity

12:30–1:45 p.m. | Room 107

Abstract 265 — FLASH radiotherapy prevents lymphopenia and downstream immunosuppression via Chk1-STAT3 axis regulation in preclinical thoracic irradiation
1:20–1:30 p.m.
Presenter: Steven Lin, M.D., Ph.D.

QP 20 — Beyond treatment: Innovations in supportive care across the radiation oncology continuum

12:30–1:30 p.m. | Room 109
Moderator: Molly Tate, Ph.D.

Question and answers
1:05–1:25 p.m.
Presenter: Molly Tate, Ph.D.

EDU 44 — Claims-based research in radiation oncology: Emerging methods and contemporary results

2:15–3:30 p.m. | Room 109

Health disparities and comparative effectiveness research
2:17–2:37 p.m. 
Presenter: Aileen Chen, M.D.

SS 38 — Imaging biomarkers

2:15–3:30 p.m. | Room 253

Abstract 308 — Patterns of nodal failure after cervical cancer chemoradiotherapy: The role of geometric miss and baseline nodal signal
2:55–3:05 p.m.
Presenter: Shiqin Su, Ph.D.

Workshop 08 — Grant writing workshop

2:15–4:15 p.m. | Room 153
Moderator: Debra Yeboa, M.D.

Introductions, NIH review criteria
2:15–2:30 p.m.
Presenter: Debra Yeboa, M.D.

Specific aims
2:30–2:45 p.m.
Presenter: Kristy Brock, Ph.D.

SS 36 — Predicting benefit and toxicity: Biomarkers in prostate radiotherapy

3:45–5 p.m. | Room 210

Abstract 315 — Long-term transcriptomic analysis of NRG/RTOG 9601: A Phase 3 study of salvage radiotherapy for prostate cancer with or without anti-androgen therapy
4:25–4:35 p.m.
Presenter: Krishnan Patel, M.D. 

SS 40 — Evolving paradigms in high-risk breast cancer: Optimization and integration of treatment modalities across the disease continuum

3:45–5 p.m. | Room 253

Discussion
4:45–4:55 p.m.
Presenter: Wendy Woodward, M.D., Ph.D.

SS43 — Palliative care in oncology

3:45–5 p.m. | Room 254

Abstract 330 — SOAR-HN: A Phase II randomized trial of stereotactic body radiotherapy vs. conventionally fractionated reirradiation for previously treated, unresectable head and neck cancer
3:55–4:05 p.m.
Presenter: Liam Spurr, M.D.

EDU 47 — Precision in practice: The use of novel biomarkers in GU cancers

3:45–5 p.m. | Room 205

Role of biomarkers in renal cell cancer
4:32–4:47 p.m.
Presenter: Chad Tang, M.D.

SS 45 — Novel treatment and safety

3:45–5 p.m. | Room 156 

Abstract 348 — Characterizing stereotactic radiosurgery plan quality across the community: Imaging and Radiation Oncology Core (IROC) Phantom Audit Program 
4:45–4:55 p.m. 
Presenter: Lian Duan 

EDU 54 — Equipping the clinician for the latest in management of challenging gliomas

5:15–6:15 p.m. | Room 162 

Molecular glioblastoma: The latest updates in classification and management 
5:17–5:32 p.m. 
Presenter: Debra Yeboa, M.D.

EDU 55 — Data to dollars: A radiation oncologist's role in advocating for the financial future of our patients and our field

5:15–6:15 p.m. | Room 109 

Provider solutions to addressing financial toxicity: Improving affordability at the bedside 
5:47–6:02 p.m. 
Presenter: Kamaria Lee, M.D.

QP 29 — Response assessment and risk stratification in gynecologic cancers: Biomarkers, imaging and outcomes

5:15–6:15 p.m. | Room 257 

Question and answers
5:50–6:10 p.m. 
Moderator: Christopher Weil, M.D.

QP 31 — Medical education/professional development quick pitch

5:15–6:15 p.m. | Room 254 
Moderator: Jie Jane Chen, M.D.

QP 32 — Patient reported outcomes/QoL/survivorship quick pitch

5:15–6:15 p.m. | Room 256 

Abstract 1189 — Development stage-specific breast dose reconstruction in childhood cancer survivors: A new foundation for subsequent breast cancer risk modeling 
5:30–5:35 p.m.  
Presenter: Taylor Meyers 

QP 34 — Skin and sarcoma shorts: Clinical highlights and recent advances

5:15–6:15 p.m. | Room 210 
Moderator: Andrew Bishop, M.D.

Abstract 1202 — The role of adjuvant primary site radiotherapy in the treatment of melanoma with perineural invasion 
5:30–5:35 p.m. 
Presenter: Riya Patel 

EDU 52 — The challenges of thoracic reirradiation

5:15–6:15 p.m. | Room 156 

Reirradiation strategies 
5:47–6:02 p.m. 
Presenter: Saumil Gandhi, M.D., Ph.D.

EDU 58 — Auto-planning in the wild: Lessons learned from clinical deployment

8–9 a.m. | Room 153 

Global implementation of RPA: Lessons from clinical integration in South Africa 
8:17–8:32 a.m. 
Presenter: Laurence Court, Ph.D.

SH 02 — Central nervous system: Science highlights

8–9 a.m. | Room 259 
Moderator/discussant: Jing Li, M.D., Ph.D.

QP 35 — Digital allies: AI tools built for the real clinical environment

8–9 a.m. | Room 160 
Moderator: David Qian, M.D., Ph.D.

Abstract 1210 — Modernizing the MD Anderson Stiefel Oropharynx Cancer Cohort Database through development and validation of automated data extraction algorithms 
8:30–8:35 a.m. 
Presenter: Waree Rinsurongkawong, Ph.D. 

QP 38 — Lung quick pitch: Oligometastatic and oligoprogressive NSCLC

8–9 a.m. | Room 156 
Moderator: David Qian, M.D., Ph.D.

Question and answer 
8:35–8:55 a.m. 
Moderator: David Qian, M.D., Ph.D.

SH 08 — Hematologic malignancies: Science highlights

9:15–9:45 a.m. | Room 109
Moderator/discussant: Jillian Gunther, M.D., Ph.D.

SS 47 — Spine SBRT: Risk, safety and outcomes

9:15–9:45 a.m. | Room 106

Abstract 355 — Prophylactic cement augmentation for patients at high risk for developing vertebral body compression fracture following spine stereotactic radiosurgery: A randomized Phase 2 clinical trial
9:15–9:25 a.m.
Presenter: Amol Ghia, M.D.

QP 41 — Biologic determinants of radiation response

9:15–10:15 a.m. | Room 157 

Abstract 1244 — Nanoray pancreas: Biomarker insights of NBTXR3 activated by radiotherapy (RT) for locally advanced or borderline resectable pancreatic cancer (LAPC or BRPC) 
9:35–9:40 a.m. 
Presenter: Kasey Cargill, M.D., Ph.D. 

SH 12 — Sarcoma and cutaneous tumors: Science highlights

10:45–11:45 a.m. | Room 106 
Moderator/discussant: Andrew Bishop, M.D.

PQA 01: Gastrointestinal cancer and central nervous system

3–4 p.m.

Abstract 2039 — Association of serum metabolomic signatures with survival in pancreatic cancer patients undergoing neoadjuvant therapy
Presenter: Diya Choudhary

Abstract 2041 — Risk factors for treatment-related effects in brainstem metastases following stereotactic radiosurgery
Presenter: Darien Colson-Fearon, M.D.

Abstract 2114 — Fifteen-year longitudinal analysis of spine stereotactic radiosurgery for metastatic thyroid cancer
Presenter: Ryan Ko, M.D.

Abstract 2134 — Comparative analysis of the impact of proton vs. photon-based chemoradiation in esophageal cancer patients on peripheral blood lymphocyte profile and clonal diversity using single cell combinational sequencing
Presenter: Steven Lin, Ph.D.

PQA 02: Pediatric cancer, sarcoma and cutaneous tumors, medical education & professional development and health services research

4–5 p.m. 

Abstract 2309 — Evaluating the effect of tumor-draining nodal irradiation by flash vs. conventional dose-rate radiotherapy of a clinically relevant melanoma mouse model
Presenter: Patrick Carriere, M.D., Ph.D.

Abstract 2321 — SATURN-STS: Phase 2 study of neoadjuvant atezolizumab with doxorubicin, concurrent atezolizumab with preoperative radiotherapy and adjuvant atezolizumab in patients with high-risk surgically resectable extremity and truncal soft tissue sarcoma
Presenter: Ahsan Farooqi, M.D., Ph.D.

Abstract 2323 — Proton vs. photon radiotherapy for patients with oropharyngeal cancer in the USA: A cost-effectiveness analysis
Presenter: Steven Frank, M.D.

Abstract 2326 — Radiation pneumonitis after contemporary whole lung irradiation in pediatric sarcomas and Wilms tumor
Presenter: Ory Haisraely, M.D.

Abstract 2337 — Outcomes following combined modality local therapy vs. surgery alone for patients with non-metastatic intrathoracic soft tissue sarcomas 
Presenter: Tejaswi Kanala, M.D., M.B.B.S.

Abstract 2354 — Long-term outcomes for localized leiomyosarcoma of the extremity and superficial trunk treated with surgery and radiation therapy
Presenter: Jordan McDonald, M.D.

PQA 03: Digital health innovation and informatics, patient safety & quality and radiation and cancer biology

10:45 a.m.–12 p.m.

Abstract 2454 — Multidisciplinary rapid access bone metastasis clinic: Expeditious workflow from referral to palliative radiotherapy
Presenter: Ahmed Fetooh, M.D.

Abstract 2469 — Incorporation of variable RBE in radiation-induced lymphopenia prediction risk modeling for proton therapy
Presenter: Madison Grayson

Abstract 2551 — Carbon ion radiotherapy synergizes with KRASG12D inhibition to overcome acquired resistance in pancreatic cancer
Presenter: Henry Meyer

Abstract 2565 — Harnessing the immune temperature to predict and personalize radiotherapy
Presenter: Awino Maureiq Ojwang, Ph.D.

Abstract 2606 — Machine learning-based prognostic clinical-genomic model of disease recurrence after chemoradiation and durvalumab in unresectable stage 2-3 NSCLC
Presenter: Kayeong Shin, M.D.

Abstract 2614 — LLM-driven extraction of NI-RADS and imaging tumor characteristics to enhance oropharyngeal cancer survivorship surveillance
Presenter: Wenye Song, M.D., Ph.D.

Abstract 2616 — Natural killer cells inhibit radiation induced anti-tumor immune responses
Presenter: Michael Spiotto, M.D., Ph.D.

Abstract 2641 — Single-dose FLASH vs. conventional-dose-rate proton effect on immune modulation in murine prostate cancer models
Presenter: Li Wang, M.D., Ph.D.

Abstract 2669 — Testing adaptive radiation fractionation in head and neck cancer using digital twins of clinical trials
Presenter: Mohammad Zahid, Ph.D.

PQA 04: Breast cancer, patient reported outcomes/QoL/survivorship, functional radiation medicine, hematologic malignancies, palliative care and international/global oncology

3–4 p.m.

Abstract 2774 — Local control in metastatic breast cancer: Outcomes of hypofractionated radiotherapy and SBRT for locoregional oligoprogression during systemic therapy
Presenter: Esengul Kocak, M.D.

Abstract 2778 — Radiation therapy for breast cancer: Impact of DNA repair gene mutations on oncologic outcomes
Presenter: Forrest Kwong, M.D.

Abstract 2797 — An analysis of acute-on-chronic pain and opioid dependency in a prospective head and neck cancer cohort treated with radiation therapy
Presenter: Md Mahin, Ph.D.

Abstract 2815 — Response-directed radiotherapy after methotrexate-based systemic therapy for patients with primary CNS lymphoma
Presenter: Ansel Nalin, M.D., Ph.D.

Abstract 2823 — Long-term skin-related quality of life in patients receiving post-operative radiation therapy for cutaneous melanoma
Presenter: Kelsey Nordlund

Abstract 2835 — Disease control following radiotherapy for limited-site relapse of follicular lymphoma
Presenter: Pranalee Patel, M.D.

Abstract 2836 — Shortening adjuvant photon and proton irradiation (SAPPHIRe-II) prospective clinical trial
Presenter: Jane Pearce, M.D.

Abstract 2857 — Skin-related quality of life during radiotherapy across diverse Fitzpatrick skin types and its association with radiation dermatitis
Presenter: Aya Salem, M.D.

Abstract 2897 — Prospective evaluation of acute cutaneous toxicity during proton vs. photon radiotherapy for patients with head and neck cancer and varied baseline skin pigmentation
Presenter: Rehema Thomas, M.D.

Abstract 2921 — Phase 2 study of low dose bridging radiotherapy prior to axicabtagene-ciloleucel in patients with relapsed/refractory follicular lymphoma
Presenter: Susan Wu, M.D.

Pres Poster 01 — Presidential science poster session showcase

4–5 p.m.

Abstract 2537 — Targeting radiation-triggered cell-surface GRP78 via antibody-drug conjugate for gastric cancer  
Presenter:  P.M. Quan Mai

PQA 05: Physics

12:30–1:45 p.m.

Abstract 2988 — A data-driven quality assurance for auto-segmentation model updates using a localized anisotropic margin metric
Presenter: Jingwei Duan, Ph.D.

Abstract 3014 — Machine learning-based prediction of regional liver volume response after radiotherapy in patients with liver malignancies
Presenter: Aashish Gupta

Abstract 3080 — Considerations of plan adaptation and CBCT-based accumulated dose in the prediction of patient-reported xerostomia post radiotherapy for oropharyngeal cancer patients
Presenter: Androniki Mitrou

Abstract 3148 — Dosimetric impact of intra-delivery motion in stereotactic body radiotherapy to the prostate and dominant lesion
Presenter: Ka Ho Tam, Ph.D.

Abstract 3171 — Real-Time tracking for MR-LINAC based spine stereotactic radiosurgery
Presenter: Zhiheng Wang, Ph.D.

Abstract 3172 — End-to-end test of using three-dimensional rotational angiogram for arteriovenous malformations GammaKnife radiosurgery with a grid phantom
Presenter: Zhiheng Wang, Ph.D.

Abstract 3177 — Imaging biomarkers for early detection, monitoring and prediction of radiotherapy-related side effects: A scoping review
Presenter: Natalie West

PQA 06: Genitourinary cancer, gynecological cancer and health care access and engagement

2:15–3:30 p.m.

Abstract 3238 — Safety and clinical outcomes of combining radiotherapy with lutetium-177-PSMA therapy in metastatic castrate-resistant prostate cancer
Presenter: Patrick Carriere, M.D., Ph.D.

Abstract 3262 — Clinical outcomes of rectal wall infiltration following hydrogel spacer placement: A single-institution retrospective study
Presenter: Zakaria El Kouzi, M.D.

Abstract 3274 — Skeletal-related events after radiotherapy for non-spine bone metastases in renal cell carcinoma
Presenter: Harshath Gupta, M.D.

Abstract 3374 — Impact of short-term ADT on survival in unfavorable intermediate-risk prostate cancer treated with proton-beam radiotherapy: A retrospective cohort study
Presenter: Kayeong Shin, M.D.

Abstract 3375 — Pelvic radiotherapy increases severe lymphopenia in prostate cancer
Presenter: Kayeong Shin, M.D.

Abstract 3741 — Molecular subtypes in patients with recurrent endometrial cancer treated with definitive radiation
Presenter: Lauren Bendesky, M.D.

Abstract 3735 — MCT inhibition targets cervical cancer in lactate enriched microenvironments
Presenter: David Lo

PQA 07: Head and neck cancer, lung cancer/thoracic malignancies and nursing and supportive care

3:45–5 p.m.

Abstract 3447 — Systemic immune activation by mRNA vaccination synergizes with immune checkpoint inhibition and radiotherapy: A single-institution analysis
Presenter: Sage Copling

Abstract 3468 — Serial MRI-informed proliferation-saturation index modeling for risk-adapted radiotherapy in HPV-positive oropharyngeal cancer
Presenter: Lois Okereke

Abstract 3522 — A randomized study of head and neck radiotherapy with or without customized 3D printed oral stents
Presenter: Anna Lee, M.D.

Abstract 3547 — Pulsed targeted consolidative radiotherapy for patients with polymetastatic NSCLC
Presenter: Jennifer Livschitz, M.D.

Abstract 3564 — Beyond overlap metrics: Uncertainty-based triage for pathology-anchored QA of nodal autosegmentation in HPV-positive oropharyngeal cancer
Presenter: Yehia Mohamed, M.D.

Abstract 3622 — Safety and efficacy of proton beam therapy vs. IMRT for postoperative radiotherapy in non-small cell lung cancer: A systematic review and meta-analysis 
Presenter: Kayeong Shin, M.D.